Use of rectal MRI evaluation of patients with rectal cancer for primary tumor staging and for identification for poor prognostic features is increasing. MR imaging permits precise delineation of tumor anatomy and assessment of mesorectal tumor penetration and radial margin risk.
with improved local control and significant effects of tumor response and downstaging. After neoadjuvant chemoradiotherapy, up to 20% of patients will have a complete pathologic response, and this feature has been associated with a very good prognosis following rectal resection. [2] [3] [4] In other patients, a significant tumor burden will remain, and these patients will have a higher risk for local and distant treatment failure. Based on these results, there has recently been significant interest in the identification of patients with pathologic complete response for consideration of organ-preserving nonsurgical treatment strategies. 5, 6 In addition, patients with poor-risk rectal cancers may benefit from intensified strategies to improve resectability and treatment completion. 7, 8 However, currently, it is not possible to accurately stratify patients to these low-and high-risk groups until after neoadjuvant treatment, surgical resection, and pathologic evaluation.
High-resolution MRI has become an important component of rectal cancer staging and multidisciplinary treatment planning, replacing other primary tumor-staging modalities in many centers. Advantages of MRI include the ability to establish 3-dimensional relationships between the tumor, rectum, mesorectum, and surrounding structures. Furthermore, the depth of mesorectal penetration in the orthogonal plane and the potential for involvement of the mesorectal fascial envelope (radial margin) may be assessed. Tumor involvement of mesorectal or pelvic lymph nodes or the presence of vascular invasion have also been identified with increasing accuracy. 9, 10 Pretreatment MRI tumor characteristics have therefore been used in an effort to classify patients with rectal cancer into good-and poorprognosis groups. These classifications are primarily based on the anatomic relationships of the tumor to a threatened radial margin, T4 involvement, or the presence of N2 disease, and have been used to stratify patients to receive either short-course (5 ϫ 5) radiotherapy vs long-course (45-50.4 Gy) chemoradiotherapy, but have not been examined as potential treatment response classifiers. There has been growing interest in the use of postchemoradiation treatment diffusion-weighted MRI to predict tumor response; however, this approach is limited by insufficient accuracy for the identification of complete responders and the requirement of posttreatment imaging to make the assessment.
Therefore, we conducted this study to evaluate the ability of tumor characteristics on pretreatment high-resolution rectal MRI to classify tumor response to neoadjuvant chemoradiation.
PATIENTS AND METHODS

Patient Identification
A consecutive cohort of patients with MRI-staged locally advanced (cT3-4 or cNϩ) rectal cancer treated with preoperative chemoradiotherapy followed by total mesorectal excision surgery at the University of Texas MD Anderson Cancer Center between September 2009 and March 2011 was identified from our colorectal cancer database, and their records were retrospectively reviewed. Primary tumor evaluation included digital rectal examination, proctoscopy, and staging with high-resolution dedicated rectal MRI before initiation of long-course neoadjuvant chemoradiation therapy. Patients were excluded if they had concurrent distant metastasis at diagnosis, received shortcourse (5 ϫ 5 Gy) radiotherapy, or if the interval from the completion of radiation to surgery was more than 16 weeks. The study was approved by the University of Texas M. D. Anderson Institutional Review Board.
Imaging Technique and Evaluation
All patients underwent high-resolution MRI of the pelvis for primary rectal cancer staging and computed tomography of the chest and abdomen to exclude distant metastases. MRI was performed on both 1.5T and 3T systems with the use of a cardiac phased-array coil with the patient in a supine position. After initial scout imaging, high-resolution sagittal images were obtained to identify the tumor within the rectum. A survey of the pelvis using axial thickslice 2D T2 fast recovery fast spin echo was completed, and additional high-resolution sequences including oblique axial perpendicular to tumor and coronal 2D T2 fast recovery fast spin echo images were acquired. Finally oblique, thin-slice 3D T2W cube images were also obtained. Intravenous contrast enhancement was not utilized. MRI characteristics assessed included depth of penetration into the mesorectum, relationship to the mesorectal fascial envelope (circumferential margin), status of the regional lymph nodes (involved, indeterminate, or negative), presence of extramural vascular invasion, and maximum tumor depth into the mesorectum as previously described. 11, 12 Specifically, lymph nodes were classified as malignant if they exhibited irregular borders, mixed signal intensity, or both. Smooth-bordered lymph nodes with homogeneous signal intensity were classified as indeterminate. If no lymph nodes were seen or small smooth homogenous lymph nodes with fatty hila were seen, they were classified as negative. All images were independently reviewed by 2 dedicated gastrointestinal radiologists who were blinded to the histopathologic outcomes.
Treatment
The neoadjuvant chemoradiation regimen consisted of pelvic external beam radiation, 45 Gy in 25 fractions over 5 weeks followed, in most cases (n ϭ 53, 87%), by a boost to the tumor of 5.4 Gy in 5 fractions, delivered as a second daily fraction in the last week of treatment, taking the cumulative dose to 50.4 Gy. In 7 (11.3%) patients with inguinal or lateral pelvic lymphadenopathy, or with adjacent organ involvement, the boost was 15.2 to 18 Gy with the use of an intensity-modulated radiation therapy technique. Radiotherapy was delivered with the use of a 3-or 4-field technique by 18-MV photons with customized blocking, with the patient in the prone position. Concurrent chemotherapy consisted of capecitabine, 1500 mg twice daily on days of radiation therapy only. In some cases, protocol-based concurrent chemotherapy included the addition of bevacizumab and erlotinib (n ϭ 6) or curcumin (n ϭ 5).
The surgical resection plan was determined based on the findings on pretreatment MRI and adhered to the principles of total mesorectal excision with en bloc resection of any adjacent involved structures and wide resection of the pelvic floor in cases of abdominoperineal resections. Involved lateral lymph nodes were surgically addressed.
Pathologic Assessment
Standard pathologic tumor staging of the resected specimen was performed in accordance with the guidelines of the American Joint Committee on Cancer. Resection specimens were oriented immediately after resection by the surgeon and pathologist, and the radial margins of resection were marked. The primary tumor was entirely embedded in paraffin, and serial sections were histologically evaluated with the use of standard hematoxylin and eosin staining. The mesorectum was manually dissected for lymph nodes, which were examined with 1 to 3 separate sections per node. Complete response was defined as the absence of viable adenocarcinoma cells in the surgical specimen (ypT0N0). Intermediate response was defined ypT1 to 2 without lymph node metastases, and poor response was defined as ypT3 to 4 or if lymph node metastases were identified.
Statistical Analysis
Patient, tumor, and MRI characteristics were evaluated with the use of descriptive statistics. The MRI characteristics were defined as categorical variables. Nonparametric data were assessed as median and interquartile range (IQR). Categorization of variables with continuous measurements (eg, depth of penetration into the mesorectum) was performed before analysis. Logistic regression analyses were performed to examine univariate associations with pathologic response. Pathologic response to treatment was defined as "good" if the final pathology stage was ypT0 to 2N0 or "poor" if it was ypT3 to 4 or ypNϩ. The complete and intermediate response categories were grouped as "good" because they have been associated with more favorable prognosis to yield a binary response classification. A multivariate logistic regression model was then constructed by the use of stepwise forward selection with the terms identified on univariate analysis. We tested for interactions between the independent variables with logistic regression and, in cases of colinearity, excluded the redundant terms in the final model. Model discrimination was evaluated by generating a receiver operator curve and determining the concordance index.
RESULTS
Patients and Treatment
A total of 62 patients met eligibility criteria and were analyzed. Median age at diagnosis was 55.5 (IQR, 47-62) years. Baseline patient and treatment characteristics are summarized in Table 1 . Most patients had distal tumors with a median distance of 6 cm from the anal verge (IQR, 4 -9 cm). All patients underwent preoperative long-course chemoradiation therapy followed by total or tumor specific mesorectal excision with en bloc resection of involved adjacent structures at a median of 8 weeks after the last dose of radiotherapy. Surgical resection was performed at a median 7.9 (IQR, 7-9) weeks after the last fraction of radiotherapy. Operations performed were low anterior resection in 15 (24.2%), proctectomy with coloanal reconstruction in 29 (46.8%), abdominoperineal resection in 12 (29.4%), and multivisceral resection in 6 (9.7%).
MRI Evaluation
Pretreatment tumor stage and MRI characteristics are shown in Table 2 . The majority of tumors had 1 to 5 mm of penetration into the mesorectum; however, 34% (n ϭ 21) of the patients had Ͼ5 mm penetration. T2 tumors were defined as having 0 mm penetration into the mesorectum. The distance from the primary tumor or involved mesorectal lymphadenopathy to the mesorectal fascia or peritoneal surface in the case of more proximal tumors was evaluated with a median distance of 4 mm (IQR, 0 -12 mm). IQR ϭ interquartile range; dAV ϭ distance from anal verge; LAR ϭ low anterior resection; CAA ϭ coloanal anastomosis; APR ϭ abdominoperineal resection; CXRT ϭ chemoradiation therapy.
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Based on pretreatment MRI, the resection margins were felt to be at risk in 24 (38.7%) of patients by either primary tumor extension to the mesorectal fascia or by metastatic lymph nodes. Lymph node metastases were assessed to be present in almost two-thirds of the patients (n ϭ 40, 61.5%), and extramural vascular invasion was identified in 16 (25.8%) patients ( Figs. 1 and 2 ).
Histopathologic Results
Complete histopathologic mural tumor regression was identified in 15 (24.2%) patients, but 5 of these patients had 1 to 5 positive lymphs, a pathologic complete response rate of 16.1% (n ϭ 10) ( Table 3) . Among patients whose pathologic radial margin status was 1 mm or less, all patients had threatened radial margins on MRI. Among the 24 (38.1%) patients with MRI-assessed threatened circumferential resection margins, the median pathologic radial margin distance was 5 mm (IQR, 1-15 mm), and none of these patients achieved a pathologic complete response.
Univariate and Multivariate Analysis
The associations between the pretreatment MRI and pathologic response are shown in Tables 4 and 5 . On univariate analysis, pretreatment MRI findings of maximum tumor depth into the mesorectum, lymph node involvement, and extramural vascular invasion but not grade were associated with poor treatment response. On multivariate analysis, MRI-identified lymph node involvement and increasing tumor depth into the mesorectum remained associated with poor pathologic response to neoadjuvant therapy. The concordance index for the model was 0.86, demonstrating good discrimination. The presence of extramural vascular invasion on MRI was associated with both lymph node involvement and greater depth of mesorectal penetration, and, after adjustment for these other variables, was not independently associated with treatment response.
DISCUSSION
In this study, we have demonstrated that high-resolution MRI staging for rectal cancer can be performed as an institutional policy within the United States and that the findings on pretreatment MRI are associated with tumor response to neoadjuvant chemoradiation therapy. Greater depth of penetration into the mesorectum and MRI-defined lymph node involvement were both independently associated with poor tumor response. Furthermore, in this group of patients with advanced disease, the identification of potential circumferential resection margin involvement by MRI was associated with a final histopathologic diagnosis of radial margin distance Յ1 mm. The findings on pretreatment MRI were therefore able to stratify patients as good or poor risk for response to neoadjuvant chemoradiation therapy. This permits targeting of good-or poorrisk patients for appropriate novel treatment strategies. Although there has been previous interest in the use of MRI to identify high-risk patients with rectal cancer for treatment stratification (eg, immediate surgery vs preoperative radiotherapy), the ability of the preoperative MRI to risk-stratify neoadjuvant chemoradiation treatment response has not been previously considered. Primary surgical treatment without radiotherapy of "good prognosis" rectal cancers within the MERCURY study (clear circumferential resection margin, no extramural venous invasion, tumor spread into mesorectum Ͻ5 mm) has been associated with a low rate of local failure. 13 However, one limitation of this approach is that these findings are based on outcomes of MRI staging performed by specially trained radiologists followed by surgical resection performed by trained surgeons. Additional limitations may exist for generalizing these United Kingdom-based study results to the US population for whom MRI staging for rectal cancer has not achieved general application. Furthermore, large-scale quality improvement programs for total mesorectal excision surgery would need to be used, as have been conducted in the United Kingdom, to ensure that patients selected for treatment with surgery alone undergo optimal oncologic resection. Thus, the MERCURY study group data provide important preliminary results to stimulate further investigation of risk-stratified treatment strategies.
There has also been interest in identifying patients for consideration of intensified treatment strategies to improve resectability of patients with poor-risk tumors. 7, 8 In addition, poor treatment response appears to indicate more aggressive tumor biology with poorer long-term outcomes than for patients with a good response; and therefore poor responders may benefit from intensified treatment strategies as well. 14 -16 The ability to risk-stratify patients for such treatments depends on an ability to identify them before neoadjuvant treatment initiation. Traditionally, this has been primarily based on the predicted status of the circumferential resection margin without information regarding the anticipated response to standard neoadjuvant chemoradiation therapy. Twenty-four patients (38.1%) in this study were noted to have threatened radial resection margins by pretreatment MRI, and 7 of these patients (29%) had yp margin status Յ1 mm, although none had a grossly positive margin. Among the remaining 17 patients (71%) in whom the margin was threatened on preoperative imaging, the median yp radial margin distance was 5 mm (IQR, 1-15) . A total of 37 (59.7%) of the study patients were observed to have poor response to neoadjuvant therapy, but only 19 would have been identified by the identification of threatened radial margins. Furthermore, the composite criteria of lymph node status and depth of mesorectal penetration as defined in this study correctly identified 17 (94%). Thus, the pretreatment imaging can be used to identify high-risk (likely CRM ϭ circumferential resection margin; IQR ϭ interquartile range.
DISEASES OF THE COLON & RECTUM VOLUME 55: 4 (2012) to have poor response) patients for novel treatment-intensified protocols such as those incorporating induction chemotherapy or expanded radiosensitizing regimens. Given the potential additive toxicity of combination chemotherapy, the selection of poor-risk patients is important, and limits the exposure to treatment-related toxicity for the good-risk groups. For as long as MRI has been considered for rectal cancer staging, there has also been interest in the use of posttreatment MRI to identify complete responders to preoperative chemoradiotherapy. Patients with complete treatment response have been considered for organ-preserving nonsurgical treatment strategies. 6 However, treatment-associated changes to the primary tumor bed with fibrosis and collapse of the rectal wall can lead to difficulty in interpretation with a high degree of interobserver variability. In expert hands, a false-positive prediction for good response within the bowel wall (ypT0 -2) will occur in 1 of 4 patients. 17 Although the addition of diffusion-weighted imaging can improve the evaluation and can decrease the interobserver variability, in particular, among radiologists with less experience in MRI for rectal cancer staging, accurate posttreatment lymph node assessment still remains a challenge, and, as of yet, there is no practical way to reliably identify complete responders. 18 Furthermore, the requirement for posttreatment imaging does not permit an opportunity for multidisciplinary treatment modification. Our results show that the pretreatment high-resolution MRI yields useful information for neoadjuvant therapy response stratification. After adjustment for covariates, tumor depth Ͼ5 mm into the mesorectum was associated with 92% lower odds of good response, and the identification of positive lymph nodes on MRI was associated with 88% lower odds of good response. Although the presence of extramural vascular invasion was an important univariate prognostic indicator on pretreatment imaging, it was rarely identified in the absence of lymph node positivity or deep tumor penetration into the mesorectum, and thus was not an independent predictor of response. To consider novel treatments that incorporate organ-preserving waitand-see type strategies for patients with pathologic complete response, it will be desirable to begin with a study cohort that has been enriched for potential responders based on pretreatment MRI.
One current limitation to the use of MRI for pretreatment evaluation is the significant learning curve associated with image evaluation, and the uncertainty regarding nodal assessment, in particular, in the era of long-course chemoradiation-associated nodal downstaging, where there are limited opportunities for histopathologic confirmation of the pretreatment radiographic assessment. At the University of Texas MD Anderson Cancer, we have incorporated routine high-resolution rectal MRI staging performed by a dedicated radiology team since September 2009. The radiologist is present during image acquisition to ensure that the axial images are obtained perpendicular to the plane of the rectum at the level of the tumor. This may not be practical in all settings, and alternative strategies for accurate imaging may need to be explored. A relatively unique feature of this cohort also was the disproportionately advanced tumor stage; a large number of patients had threatened circumferential resection margins, and the majority of the patients were noted to have lymph node metastases on initial imaging. However, the rate of pathologic complete response was still 16%, consistent with previous reports from our institution and others. 14, 15 In addition, there may be inherent limitations of MRI, such as to distinguish a T2 lesion from a very early T3 lesion with Ͻ1 mm mesorectal penetration. There were 11 patients in that category in this cohort, all of whom ultimately underwent neoadjuvant chemoradiation therapy based on clinical nodal involvement. Recognizing this, we felt it was appropriate to focus on the final pathology stage as an overall indicator of response based on the clinical interpretation of the MRI that led to the recommendation for neoadjuvant therapy (eg, stage mrII-III). Finally our analysis was designed not with the goal to definitively predict pathologic complete response, but rather with the aim to classify patients as highly or not likely to exhibit a good response to neoadjuvant therapy before treatment. Although it stands to reason that more advanced tumors were less likely to respond to neoadjuvant therapy, our results provide a semiquantitative indicator of the extent to which the tumor burden can affect response.
CONCLUSION
Primary rectal cancer tumor characteristics on high-resolution MRI obtained before neoadjuvant chemoradiation are strongly associated with neoadjuvant treatment response. These factors should therefore be considered for stratification of patients for novel treatment strategies reliant on pathologic response to treatment or for the selection of poor-risk patients for intensified treatment regimens.
